

APOS
2021

Program of Events



and Beyond

Emerging Technologies in Precision Oncology

Monday 22nd November 2021 - 5pm - 7pm

*The Future of Genomic Cancer
Medicine*

Tuesday 23rd November 2021 - 5pm - 7pm

Informatics and Novel Technologies

Wednesday 24th November 2021 - 5pm - 7pm

*The Value of Precision Oncology: A
Health Systems Perspective*

Thursday 25th November 2021 - 5pm - 7pm

*Risk Management in the
Genomic Era*

Australian
Precision Oncology
Symposium

Brought to you by:



With support from:



Monday 22nd November
2021
5pm - 7pm AEDT



Welcome	David Thomas
Plenary lecture <i>Creating new trial infrastructures to support precision medicine: successes, hurdles and lessons</i>	Emile Voest Medical Oncologist Director, Cancer Core Europe Senior Group Leader Translational Scientist
Therapeutic Program Update Session chair and moderator: Professor John Simes	
Pan cancer	David Thomas Medical Oncologist Head, Genomic Cancer Medicine CEO Omico
Pancreas	David Goldstein Clinical Professor, CI MoST-Pancreas
Aspiration - Lung cancer	Nick Pavlakis Medical Oncologist, Chair, TOGA Co-chair ASPIRATION
Leukaemia/haematology	Steven Lane Clinician scientist, CI for MoST-LLY
Statistical insights into basket trial data	Ian Marschner Professor of Biostatistics

Prof **Emile Voest** is medical oncologist, senior group leader at the Netherlands Cancer Institute, senior scientist of the Onco Institute, and translational scientist. He is the current director of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. His laboratory group is devoted to bringing precision medicine to patients and is focused on mechanistic studies of tumor biology, immunology and applying computational science and genomics to better understand how tumors respond to certain treatments. The results from these studies are subsequently tested for their value in patients. These translational approaches are performed across tumor types with emphasis on epithelial tumors. His research is in the area of precision medicine and consists of large scale genomic sequencing of patients with metastatic cancer, the development of co-culture models of primary cultures of tumors (i.e. organoids) and immune cells to improve drug development and immunotherapy and to determine which treatment is best for a specific patient via computational, integrated approaches.



Prof Emile Voest



Prof David Thomas

Prof **David Thomas** is a medical oncologist, Head of Genomic Cancer Medicine at the Garvan Institute of Medical Research and Chief Executive Officer of Omico. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer. Prof Thomas founded the Australasian Sarcoma Study Group, a national research organisation, and established Australia's leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Dr Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centres in 7 countries, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. Since moving to NSW, he has established the Australian Genomic Cancer Medicine Centre t/as Omico, a national precision medicine program for patients with rare and early onset cancers.

Prof **Nick Pavlakis** is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Professor, Faculty of Medicine University of Sydney. He is current Board Chair of the Thoracic Oncology Group of Australasia (TOGA), member of the Upper GI Working Party of the Australasian Gastrointestinal Trials Group (AGITG) and centre lead of the ENETS Centre of Excellence - RNSH NET service. He has extensive experience in clinical research leadership in national and international clinical trials in lung cancer, mesothelioma and GI cancers. He is study co-chair of the TOGA ASPIRATION study.



Prof Nick Pavlakis

Prof **David Goldstein** is a conjoint clinical professor. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. His clinical interests are treatment of GI malignancies in particular pancreas, hepatobiliary and upper GI malignancy but also colorectal cancer, anal carcinoma and GIST. He was the Director of the UNSW Translational Cancer Research Network for the past five years and is a member of the Rare Cancer Portal leadership group. He is the co-ordinator of the Cancer Institute NSW Pancreas Cancer Translational Program Grant.



Prof David Goldstein

Prof **Steven Lane** is a clinician scientist studying the clinical management and basic translational science of myeloid blood cancers. He is a national leader in the field of haematology, President of the Haematology Society of Australia and New Zealand, a member of the National Blood Cancer Taskforce and an active member of the Australasian Leukaemia and Lymphoma Group. He is a senior clinical haematologist at Royal Brisbane and Women's Hospital, Director of Research for Cancer Care Services and head of the Cancer Program at QIMR Berghofer Medical Research Institute. He is chief investigator for the haematology arm of MoST, known as MoST-LLY.



Prof Steven Lane



Prof Ian Marschner

Prof **Ian Marschner** is Professor of Biostatistics at the University of Sydney and Head of Biostatistics at the NHMRC Clinical Trials Centre. He has 30 years of experience as a biostatistician working on clinical trials and epidemiological research in cardiovascular disease, oncology and infectious diseases. His research also focuses on the development of new statistical methodology, particularly for designing and analysing clinical trials. Formerly he was Director of the Asia Biometrics Centre with Pfizer, Head of the Department of Statistics at Macquarie University, and Associate Professor of Biostatistics at Harvard University

Brought to you by: With support from:



Tuesday 23rd November
2021
5pm - 7pm AEDT



Welcome	David Thomas
Plenary lecture <i>Real World Evidence for the Advancement of Precision Medicine</i>	Cheryl Cho-Phan Medical Director at Flatiron Health
Novel Technologies Session chair and moderator: Dr Maya Kanzara	
Microbiomics	Lutz Krause Chief Scientific Officer, Microba
Glycobiomics	Klaus Lindpaintner Chief Scientific and Medical Officer at InterVenn Biosciences
Proteomics	Roger Reddel Director of CMRI and Head Cancer Research Unit Co-Director ProCan
Clinical Informatics <i>The TOPOGRAPH knowledgebase: rethinking therapeutic actionability in precision oncology.</i>	Frank Lin Medical oncologist Academic clinical informatician



Cheryl Cho-Phan is a medical oncologist and serves as a medical director at Flatiron Health, where she leverages her experience as a clinician and researcher to accelerate learning through the generation of real-world evidence in order to improve patient care and outcomes. Prior to joining Flatiron, Cheryl worked at Syapse as Director of Medical Oncology. Before Syapse, Cheryl was a clinical assistant professor in the Department of Medicine, Division of Oncology at Stanford University where she was a clinical trial investigator focused on the care of patients with gastrointestinal malignancies. Cheryl received her undergraduate degree in Environmental Studies from Brown University and her medical degree from Georgetown University. She completed her internal medicine residency at Oregon Health Sciences University, and medical oncology fellowship at Stanford University.

Associate Professor **Lutz Krause** is an internationally recognised expert in the application of big data methods to understand molecular biology who oversees the biostatistics work at Microba. As Chief Scientific Officer, his expertise in identifying therapeutic leads and developing diagnostics using artificial intelligence plays an integral role in meeting clinical needs with diagnostic and therapeutic assets. Associate Professor Krause received his PhD in Bioinformatics and Genome Research from Bielefeld University, Germany and has worked with numerous high impact research teams, including the Nestlé Research Institute where he studied the role of the gut microbiota in health and disease. Following his research at Nestlé he was recruited to QIMR Berghofer to head the Bioinformatics team and in 2014 he joined The University of Queensland as Principal Research Fellow. Associate Professor Krause continues to lead diagnostic and therapeutic work in key areas of human health and disease with Dr Páirc Ó Cuív.



Klaus Lindpaintner, MD, MPH, FACP, Chief Scientific and Medical Officer at InterVenn Biosciences, previously held senior positions at Pfizer as Sr. VP and Global Head, Human Genetics and Computational Biomedicine, at Hoffman-La Roche, as Distinguished Scientist and Global Head, Roche Center for Medical Genomics, spearheading the company's efforts in personalized health care; as CSO at ThermoFisher Scientific; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities, and non-governmental organizations on issues related to the successful implementation and leverage of novel technologies in health care. Klaus graduated from Innsbruck University Medical School with a degree in medicine, and from Harvard University with a degree in public health. He pursued post-graduate training and specialization in internal medicine, cardiology, and clinical and molecular genetics in the US and Germany and is a Diplomate of the Boards in these specialties.

Professor **Roger Reddel** (AO BSc (Med) MBBS PhD FRACP FAAHMS FAA) is a medical oncologist, molecular geneticist and an internationally renowned expert on cancer cell immortalisation. He is Director of Children's Medical Research Institute (CMRI), Westmead, a Fellow of the Australian Academy of Science, and a Fellow of the Australian Academy of Health and Medical Sciences. He is also Head of CMRI's Cancer Research Unit, Director of CellBank Australia and Co-Director of ProCan@. Professor Reddel was elected as a Fellow of the Australian Academy of Science and of the Australian Academy of Health and Medical Sciences, and has been awarded the Ramaciotti Medal for Excellence in Biomedical Research, the NSW Premier's Award for Outstanding Cancer Researcher of the Year, and the Neil Hamilton Fairley Medal of the Royal Australasian College of Physicians. He serves on many medical research advisory panels. In 2021, he was awarded an Order of Australia.



Dr **Frank Lin**, NHMRC Clinical Trials Centre, University of Sydney; Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research. Dr Lin is a medical oncologist and an academic clinical informatician, with specific research interests in precision oncology, decision support, and application of artificial intelligence in cancer medicine.

Wednesday 24th November 2021
5pm - 7pm AEDT



The rapid development in Precision Oncology over the past decade represents great hope and opportunity for Australians living with cancer. However it also brings significant challenges to the way our health system has traditionally dealt with, delivered and funded cancer treatments.

Join us for a stimulating discussion with 4 global thought leaders in the field led by Richard Vines.

Welcome and introduction	Richard Vines CE of Rare Cancers Australia Chair, NOA
---------------------------------	--

Global thought leaders in the field:

Donald Husereau Professor of Medicine and Senior Associate Institute of Health Economics	Vivek Muthu Specialist in Health Systems and Value
Stephen Fox Director of Pathology	Graeme Suthers National Director of Genetics, Sonic Pathology



Don Husereau an Adjunct Professor of Medicine at The University of Ottawa and Senior Associate with the Institute of Health Economics. He has expertise in health technology and policy assessment, and health economics and was a former Director and Senior Advisor for the Canadian Agency for Drugs and Technologies in Health. Don's current research focuses on appropriate and innovative approaches to the use of evidence and economics to inform health policy based on sound principles of social justice, epistemology, and judgment and decision-making. He has done extensive commissioned work on the value of innovation in health care for Health Canada's Federal Commission on Innovation (the Naylor commission), CIHI, the Applied Research and Analysis Directorate, and CADTH. He is currently Chair of an International Task Force that has developed consolidated health economic evaluation reporting standards (CHEERS) that is now endorsed by leading biomedical and health policy journals. Don is currently an Editorial Advisor for the biomedical journals, Value in Health and BMC Medicine. He is also Senior Scientist at the University for Health Sciences, Medical Informatics and Technology in Hall in Tiro, Austria. Most recently, Don served on the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) and currently serves on the Ontario Committee to Evaluate Drugs. Don received both his BSc and MSc from the University of Alberta's faculty of Pharmacy and Pharmaceutical Sciences.

Dr **Vivek Muthu**, Director, Marivek Health; Specialist in Health Systems and Value, specialises in health system improvement. After training in clinical medicine and epidemiology, he founded Bazian, a company focusing on the application of analytics and evidence to deliver high quality, safe, effective care and to maximise health resource utilisation and outcomes, working with payers and health systems across the world. He sold Bazian to The Economist Group, to found and grow its global healthcare practice under his leadership.

A consultant now to companies including the Economist Group, the European Bank for Reconstruction and Development, and large life sciences corporations, Vivek additionally holds advisory and Board roles with smaller companies in the biotech, data analytics and health systems strategy arenas. An experienced speaker and moderator, he is a regular contributor to international summits and round tables for the Economist Group, for industry, for policy-makers, NGO and third sector participants in healthcare. Vivek is a founding member of All.Can, an NGO dedicated to improving patient-centred outcomes in cancer care.



Richard Vines, Chief Executive, Rare Cancers Australia (RCA). Richard and his wife, Kate established RCA in June 2012. The not-for-profit provides support to all Australian patients diagnosed with a rare or less common cancer - because rare does not mean you have to be alone. His strong advocacy achievements in policy reform around research and access to treatments, wide influence and significant expertise have also led to Richard taking on several other leadership roles within peak oncology and research bodies including:
Convener and Chair of the National Oncology Alliance
Chair of the Australian Genomics Health Alliance's Community Advisory Board
Deputy Chair of the Australian Genomics Cancer Medicines Program (Omico)
Committee member of All.Can Australia
Committee Member of the Patient Voice Initiative
Richard also serves as an associate investigator on a number of research projects and is a highly sought after speaker and spokesperson for cancer patient advocacy issues, both in Australia and across the Asia Pacific region.

Prof **Stephen Fox** is Director of Pathology at Peter Mac and Professorial Fellow in the Department of Pathology, The University of Melbourne. He received his medical training in Bristol (UK) and completed his pathology training in Oxford (UK). He was awarded a DPhil (Oxford) for work in angiogenesis and human cancer. He spent some time in New Zealand, and moved to Australia in 2006. The focus of his work is on prognostic and predictive markers together with the molecular pathology of cancer. Being a Clinical Pathologist, he focuses on translating many of the genomic tests, including KRAS, BRAF, ALK and HER2, in colorectal, breast, lung and melanoma. He is recognised as an expert in breast and molecular pathology.



Prof **Graeme Suthers** is the national Director of Genetics for Sonic Pathology Australia. He trained in clinical and laboratory genetics in Sydney, Adelaide, and Oxford, and held senior appointments in the South Australian public sector prior to his appointment with Sonic. His current role involves the development of genetic services for patients and families across Sonic's clinical and laboratory services Australia-wide. He has been a member of a number of professional and Government committees involved in implementing cost-effective genetic services of high quality.

Brought to you by: With support from:



Thursday 25th November
2021
5pm - 7pm AEDT



Session chair and moderator: Mandy Ballinger

Welcome	Mandy Ballinger
Managing heritable cancer risk in the genomic era	Mandy Ballinger Head, Clinical Cohorts Omico Group Leader, Garvan
Psychological and behavioural responses to germline sequencing	Phyllis Butow Emeritus Professor Chair PiGeOn
Germline findings in MoST	Milita Zaheed Medical Oncologist Cancer Genetics Specialist
Life experience	Samantha Arthur Li Fraumeni Syndrome Association
Consumer's perspective Q&A Panel	Christine Cockburn Head of Patient Support Samantha Arthur Brett Campbell




Dr **Mandy Ballinger** (BSc(Hons), MGenCouns, PhD) is a Group Leader at the Garvan Institute of Medical Research and Head of Cohorts for Omico. Her clinical training includes a Masters in Genetic Counselling. She oversees a program of work focused on defining heritable cancer risk which includes the International Sarcoma Kindred Study, with over 3600 families enrolled internationally, and more recently the Genetic Cancer Risk in the Young Study. Dr Ballinger was key to establishing SMOC+, the Australian whole body MRI study for individuals with multi-organ cancer prone syndromes. Her work in Li Fraumeni syndrome has impacted clinical practice internationally. Dr Ballinger continues to use research cohorts as vehicles for intervention to impact on clinical practice and improve outcomes for individuals and their families.

Prof **Phyllis Butow** (BA(Hons), MPH, MCLinPsych, PhD) is Emeritus Professor, and NHMRC Senior Principal Research Fellow in the School of Psychology at the University of Sydney. She founded the Australian Psycho-Oncology Co-operative Research Group (PoCoG) and the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED). Prof Butow has worked for over 30 years leading research in health professional-patient communication and Psycho-Oncology. She has conducted research on psychosocial issues in cancer genetics, doctor-patient communication, patient involvement in cancer consultations and decision-making (including informed consent), interventions to reduce fear of cancer recurrence, implementation of clinical pathways for anxiety and depression in cancer patients, and disparities in outcomes and needs of immigrants with cancer. Over the past four years she has led a program of work on psychosocial, behavioural and ethical issues in cancer patients receiving whole genome sequencing and tumour mutation profiling testing and results (the PiGeOn study). She has won many awards, including the International Psycho-Oncology Society Bernard Fox award for outstanding contribution to Psycho-Oncology research in 2009, the Clinical Oncological Society of Australia Tom Reeve award for outstanding contribution to cancer care in 2011, NSW Cancer Researcher of the year in 2012, and an Order of Australia (AM) in 2014.



Dr **Milita Zaheed** is a Medical Oncologist and a Staff Specialist in Cancer Genetics at Prince of Wales Hereditary Cancer Centre. She is undertaking a PhD titled "Germline Cancer Predisposition in the Genomic Era of Cancer Care" under the supervision of Dr Mandy Ballinger and Prof David Thomas through a scholarship with Omico. She is part of the Molecular Screening and Therapeutics (MoST) program's molecular tumour board as a germline expert. She is an active committee member and previous Deputy Chair of the Young Oncologist Group of Australia (YOGA).

Ms **Samantha Arthur** is co-chair of the Li Fraumeni Syndrome Association Australia/New Zealand Chapter and is a member of the Cancer Risk and Early Detection Working Group of Omico. Ms Arthur comes from a family that has been impacted by a multi-organ cancer prone syndrome across several generations. She is a co-investigator on several grants investigating clinical and psychosocial aspects of surveillance in high cancer risk individuals.



Ms **Christine Cockburn** is the Head of Patient Support and Operations at Rare Cancers Australia (RCA). She is a health sociologist and is currently undertaking a Masters in Public Health at Monash University. Christine is passionate about patient empowerment and equity of patient outcomes. She combines this drive and her expertise in the field with the power of lived experience - as a breast cancer survivor herself and previously caring for her mother who was diagnosed with a rare cancer - to lead the Patient Support team at the heart of RCA.

Brought to you by: With support from:

